Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Deffered Revenue (2023 - 2024)

Historic Non-Current Deffered Revenue for Gain Therapeutics (GANX) over the last 2 years, with Q4 2024 value amounting to $47441.0.

  • Gain Therapeutics' Non-Current Deffered Revenue fell 4994.94% to $47441.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $47441.0, marking a year-over-year decrease of 4994.94%. This contributed to the annual value of $47441.0 for FY2024, which is 4994.94% down from last year.
  • According to the latest figures from Q4 2024, Gain Therapeutics' Non-Current Deffered Revenue is $47441.0, which was down 4994.94% from $65869.0 recorded in Q3 2024.
  • Gain Therapeutics' 5-year Non-Current Deffered Revenue high stood at $608982.0 for Q2 2023, and its period low was $47441.0 during Q4 2024.